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Abstract: A label-free sensor, based on the combination of silicon photonic bandgap (PBG) 
structures with immobilized molecular beacon (MB) probes, is experimentally developed. 
Complementary target oligonucleotides are specifically recognized through hybridization 
with the MB probes on the surface of the sensing structure. This combination of PBG sensing 
structures and MB probes demonstrates an extremely high sensitivity without the need for 
complex PCR-based amplification or labelling methods. 
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1. Introduction 
The use of oligonucleotides, short sequence nucleic acid strands, as indicators related to 
different biological functions is attracting a great interest during the last years. Some 
examples of these oligonucleotides are miRNAs, siRNAs or tRNAs, which play an important 
role in the regulation of gene expression [1–3], cell differentiation and proliferation [4–7], 
developmental timing [8–11], neural development [12] and apoptosis [13], among others. 
Moreover, the dysregulation of some of these oligonucleotide functions are also linked to 
several diseases, such as diabetes [14–16], neurodegenerative disorders [17–19] and cancer 
[20–23], making them perfect candidates to be used as clinical diagnostic and therapeutic 
biomarkers. In this context, the development of high-throughput, sensitive, and rapid 
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oligonucleotides detection methods has become an important topic of research for the 
biomedical community. 
Northern blot and real-time quantitative polymerase reaction (qPCR) techniques are 
currently considered the benchmark methods for oligonucleotides detection [24,25]. Despite it 
is used for the identification of several novel miRNAs [26], northern blot analysis provides a 
poor sensitivity, requires large amounts of sample input and is extremely laborious and time-
consuming [27]. In contrast, qPCR can cover a broad range of oligonucleotide concentrations 
with a relatively high sensitivity, but it requires using highly purified targets, which can 
introduce a large variability and lead to inaccurate analyses [28]. Furthermore, labelling 
process is indeed a major requirement for these assay methods in order to increase both 
sensitivity and selectivity, making the detection slower, expensive and less reliable [29,30]. 
On the other hand, label-free detection technologies are rapidly evolving as alternative 
means for detecting a wide range of biomolecules in a simpler and more efficient way [31]. 
Among the different transduction technologies considered for these developments, planar 
integrated photonic technology presents advantages such as high sensitivity, compactness, 
high multiplexing level, shorter time to result, need of very low sample and reagent volumes, 
immunity to electromagnetic interferences and compatibility with CMOS (Complementary 
Metal-Oxide-Semiconductor) technology fabrication [32–34]. Oligonucleotides detection has 
already been demonstrated using photonic based sensors such as ring resonators [35–38], 
photonic crystals [38,39], Mach-Zehnder interferometers [40,41] or bimodal waveguides [42], 
exhibiting outstanding performance. 
In this work, we report the development of a planar integrated photonic sensor for label-
free oligonucleotide detection, comprising a photonic bandgap (PBG) structure 
biofunctionalized with molecular beacon (MB) recognition probes. The combination of these 
two transduction and biorecognition elements has allowed obtaining a very high spectral 
sensitivity towards the detection of target oligonucleotides while keeping a sensor footprint 
below 100 µm2. 
2. Sensor concept 
2.1. Photonic bandgap sensing structures 
PBG structures, which are created by introducing a periodic modulation in the refractive 
index of the photonic structure, are one of the most promising candidates for the creation of 
high performance analysis devices [43,44]. In these structures, the position of the PBG, i.e., 
the spectral range where the propagation of the light is not allowed due to the periodicity of 
the structure, is shifted when a target analyte/substance interacts with them due to the local 
variation of the refractive index that is produced, as shown in Fig. 1. So, the extend of the 
biointeraction (or the amount of analyte accumulated on the surface) can be detected and 
quantified in real time by monitoring the shift of the PBG of the sensing structure. 
One of the most relevant characteristics of PBG structures as sensors is that their periodic 
configuration allows increasing the sensitivity on account of the enhanced interaction of the 
optical field with the targets due to the slow-wave effect [45,46], which makes the detection 
of very low analyte concentrations possible. In addition, their extremely reduced size, 
typically in the range of several tens of µm2, allows integrating many of these sensing 
structures on a much reduced area to perform a multi-analyte detection. Thus, PBG designs 
are a ground-breaking class of refractive-index-sensitive structures to monitor chemical 
and/or biochemical binding events. 
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 Fig. 1. Ideal transmission spectra for a PBG structure a) before the biomolecular interaction 
and b) after the biomolecular interaction, where a shift of the PBG is produced. 
2.2. Molecular beacon probes 
A MB probe consists on a single stranded oligonucleotide having a stem-loop configuration 
in its initial state [47,48]. Once hybridized with the complementary strand, the MB opens the 
stem adopting the double helix configuration. The typical application of MB is depicted in 
Fig. 2 [49], where a fluorescent label (reporter) and a quencher are attached to the 5′ and 3′ 
ends of the MB, respectively. Thus, when the hybridization takes place, the conformational 
change in the MB separates the quencher from the reporter, restoring the fluorescence. This 
fluorescence-based MB approach is widely used for oligonucleotide detection in 
homogeneous assays [50,51], but its performance is limited by the difficulty of detecting the 
small fluorescence changes produced by small oligonucleotide concentrations. Very few 
examples are found where the MB is used in an heterogeneous assay being immobilized onto 
a solid substrate [52,53]. 
 
Fig. 2. Schematic explanation of the working principle of a fluorescence-based MB probe for 
oligonucleotide detection. 
In the present work, instead of using the fluorescence-based configuration previously 
described, we directly immobilized MB on the surface of the PBG sensing structure, as shown 
in Fig. 3. In this way, the hybridization of the target oligonucleotides with the MB probes will 
induce a change in the response of the photonic sensing structure not only due to 
hybridization events, as it happens for typical linear oligonucleotide probes, but also by the 
contribution of the conformational change of the MB probes. 
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 Fig. 3. Scheme of the hybridization event having the MBs immobilized on the surface of a 
photonic structure. 
3. PBG sensing structure design 
The PBG sensing structure used in this work consists on a silicon 1D periodic configuration 
created by introducing straight transversal elements in a single mode waveguide placed on top 
of a silicon oxide lower cladding, as shown in Fig. 4. The optimal configuration of the PBG 
sensing structure was determined by means of Plane Wave Expansion (PWE) and Finite-
Difference Time-Domain (FDTD) simulations, considering a refractive index of nSi = 3.4777 
for the silicon and of nSiO2 = 1.444 for the silicon oxide. 
 
Fig. 4. Schematic representation of the 1D PBG sensing structure. Note that it is considered 
that the silicon periodic structure is placed on top of a silicon oxide lower cladding. 
First, PWE simulations were done using MIT Photonic Bands (MPB) software in order to 
obtain the band diagrams for the different potential configurations of the periodic structure. In 
these simulations, TE modes were considered, as PBGs only appear for this polarization in 
periodic structures having a dielectric continuity. Additionally, only modes having an even in-
plane symmetry were analyzed, as only those will be excited when accessing the periodic 
structure using a single mode waveguide. An example of band diagram for TE even modes is 
shown in Fig. 5(a), where it can be observed that up to two PBGs can potentially appear 
(between the first and the second bands and between the second and the third bands). From 
these simulations, the position of the PBG edges of the periodic structure was determined 
when considering a water upper cladding (nwater = 1.333) as well as their sensitivity to bulk 
refractive index variations. 
Then, FDTD simulations were carried out using CST Microwave Studio to obtain the 
transmission spectral response for those configurations having any of their PBG edges located 
at 1550 nm. The simulation region considered a 750nm-high silicon oxide lower cladding and 
a 750nm-high upper cladding above the PBG sensing structure, and a 3000nm width in the 
transversal direction. The boundary conditions were all open add space and a symmetry plane 
was specified, located in the center of the waveguide and along the light propagation 
direction, as electric plane so as to reduce the simulation time. An example of FDTD 
transmission spectrum is shown in Fig. 5(b), where an inset of the electric field distribution 
(TE mode) along the PBG sensing structure at λ = 1550 nm is inserted. In these simulations, 
                                                          Vol. 9, No. 4 | 1 Apr 2018 | BIOMEDICAL OPTICS EXPRESS 1722 
we looked for those configurations of the periodic structure providing a deep PBG region and 
a sharp PBG edge. 
 
Fig. 5. (a) Example of MPB band diagram of the 1D PBG sensing structure. Bands depicted in 
red and blue colors represent the band diagram for a water (n = 1.333) and a silicon oxide (n = 
1.444) upper cladding, respectively. Up to two PBGs can appear (depicted in shaded red 
color): one between the first and the second guided bands and another between the second and 
the third guided bands. The grey shaded area depicts the band diagram region being below the 
light line of the silicon oxide; modes within this region will not be confined in the vertical 
direction and will leak into the silicon oxide lower cladding, so they are not considered for 
determining the PBGs position. (b) Example of CST transmission spectrum of the 1D PBG 
sensing structure. Transmission spectra for a water and a silicon oxide upper cladding are 
depicted in red and blue colors, respectively. The two PBGs observed in the MPB band 
diagrams are also obtained in these simulations. The inset shows the electric field distribution 
(TE mode) along the PBG sensing structure at λ = 1550 nm. 
The selected optimal configuration consisted on a single mode waveguide of width w = 
460nm and height h = 220nm where transversal elements, of width wi = 120nm and length we 
= 1500nm, are introduced with a periodicity of a = 380nm. This configuration has the upper 
edge of its second PBG located at 1550 nm for a water upper cladding and provides a 
theoretical sensitivity to bulk refractive index variations of 175 nm/RIU (Refractive Index 
Units). 
4. Fabrication and biofunctionalization 
4.1. Photonic chip fabrication 
Figure 6(a) shows a picture of the fabricated photonic chip created in a silicon-on-insulator 
(SOI) substrate using e-beam lithography with an acceleration voltage of 100 keV and 
inductively coupled plasma etching of the top silicon layer. Four PBG sensor pairs separated 
a distance of 1.5 mm were included in the chip in order to have the possibility of 
biofunctionalizing each of them in a different manner. Each pair comprises two PBG sensing 
structures having a different width of the transversal elements (wi = 120nm and wi = 140nm) 
in order to compare their sensing performance. Figure 6(b) shows a scanning electron 
microscope (SEM) image of one of the PBG sensing structures fabricated in the photonic 
chip. The chip was accessed at the input and the output via 70 nm-deep shallow etch 1D 
grating couplers. A multi-mode interferometer (MMI) splitter was used before each PBG 
sensor pair in order to excite both structures using the same access grating coupler, what 
allows reducing the number of input coupling structures. Finally, three reference waveguides 
were also included in order to ease the alignment process when measuring the photonic chip. 
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 Fig. 6. (a) Image of the photonic chip fabricated in SOI technology. The circles depict the 
position of each PBG sensor pair. (b) SEM image of a fabricated PBG sensing structure. 
4.2. Biofunctionalization 
Thiol-ene coupling (TEC) chemistry was selected for the covalent attachment of thiolated MB 
probes to the previously derivatized PBG sensing structures [54], following the 
biofunctionalization schematic diagram shown in Fig. 7(a). This approach allows the 
biocompatible, rapid and homogeneous biofunctionalization of the structure under mild 
conditions, using UV light. To this aim, alkene groups are introduced on the chip surface by 
immersion in vinyltriethoxysilane, 2% in toluene, for 2 hours. Then, after rinsing the chip 
with acetone and curing it at 80°C for 30 minutes, an aqueous solution of thiolated MB 
probes, 10 μM, is spotted over two of the four PBG sensor pairs of the chip and irradiated at 
254 nm for 30 seconds to induce photoimmobilization. Finally, the chip is washed with PBS-
T, ultrapure water and dried with air. Immobilization densities of 14 pmol/cm2 were obtained 
following this procedure, as previously reported in [54]. The entire surface of the waveguide 
was homogeneously covered with MB probes as demonstrated by confocal fluorescence 
microscopy (CFM) analysis using the probe labelled with a fluorophore (Fig. 7(b)). One of 
the other two sensor pairs of the chip was spotted with a blocking solution of BSA (Bovine 
Serum Albumin, 2% in ultrapure water), incubated for 2 h, and rinsed. The lasting pair of the 
chip was left unmodified. Those two pairs were used as references. 
 
Fig. 7. (a) Schematic diagram of the photonic chip biofunctionalization. Each PBG sensing 
structure is represented by a blue rectangle. The arrow indicates the microfluidic flow 
direction. (b) CFM image of the biofunctionalized PBG structure using fluorophore labelled 
MB probes. 
A 35-mer target oligonucleotide sequence was selected for the sensing experiments and a 
Cy5 fluorescent label was included to confirm the effective hybridization with the MBs 
immobilized in the surface of the PBG sensing structures once the experiment is finished. An 
optimal MB probe was designed for the detection of this target oligonucleotide. In Table 1 
respective sequences are indicated. 
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Table 1. 35-mer target oligonucleotide sequence and optimal MB probe sequence 
designed for its detection. 
 
5′ 3′ Sequence (5′-3′) 
Target Cy5 AUCGACUUAAUGCUAAUCGUGAUAGGGGUGUCGU 
MB SH  ATCGACACCCCTATCACGATTAGCATTAAGTCGAT 
5. Experimental results and discussion 
5.1. Experimental setup 
The biofunctionalized chip is assembled with a polydimethylsiloxane (PDMS) flow cell 
having a 400 µm-wide and 50 µm-high microfluidic channel for sample delivery. The 
assembled chip is placed in an automated optical characterization setup able to continuously 
acquire the spectral response of all the photonic structures within the chip. Light from a 
continuous sweep tunable laser (Keysight 81980A) is coupled to the access grating couplers 
using a fiber aspheric collimator (Thorlabs CFS2-1550-APC). The light from the output 
grating couplers is collected with an objective (20X Olympus Plan Achromat, 0.4 NA) and 
measured using an infrared (IR) camera (Xenics Xeva-1.7-320). The interrogation platform is 
controlled using a software programmed in LabVIEW able to synchronize the continuous 
sweep of the laser with the image acquisition of the IR camera via a trigger signal in order to 
obtain the spectra of the photonic structures with the desired spectral resolution. The system 
is configured to acquire the spectra in the range from 1520 nm to 1620 nm with a sweeping 
speed of 10 nm/s (i.e., the spectra of all the photonic structures within the chip is acquired 
every 10 seconds) and a spectral resolution of 20 pm (the IR camera works at 500 fps). The 
target solutions are flowed using a syringe pump working in withdraw mode and set to a 
constant flow rate of 20 μl/min. 
5.2. Oligonucleotide biorecognition experiment 
Figure 8 shows the spectral evolution of the upper edge of the second PBG of the sensing 
structures for the oligonucleotide biorecognition experiment. This PBG edge was initially 
located at λ≈1570nm and λ≈1595nm for the configurations having a width of the transversal 
elements of wi = 120nm and wi = 140nm, respectively. Firstly, saline-sodium citrate (SSC) 
buffer 5X was flowed to obtain the baseline of the sensing structures. Secondly, a solution of 
0.5 µM of the fluorescence labeled target oligonucleotide, in SSC 5X, was flowed over them 
for 10 minutes. Finally, SSC 5X was flowed again in order to remove any non-hybridized 
oligonucleotide present in the medium. Note that the access section of the PBG sensor pair 
left unmodified (i.e., without the MB probes or the BSA blocking) was damaged and no 
output signal was measured for these sensors, thus leaving only the two structures blocked 
with BSA as references. 
From Fig. 8(a), it can be observed that a significant shift of the PBG edge position is 
produced when the target oligonucleotide is flowed over the PBG sensing structures 
biofunctionalized with the MB probes. This shift, typical for binding processes [55–57], 
remains unchanged when SSC 5X buffer is flowed again, indicating that the target 
oligonucleotide effectively and irreversibly hybridizes with the MB probe under the given 
conditions. On the other hand, Fig. 8(b) shows that the PBG sensing structures blocked with 
BSA do not show a net shift when SSC 5X buffer is flowed again after the oligonucleotide 
flow, indicating that the blocking BSA layer properly avoids the unspecific adsorption of the 
target oligonucleotide to the PBG sensing structures. 
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 Fig. 8. Spectral evolution of the PBG edge position for the sensing structures within the 
photonic chip when the target oligonucleotide is flowed over their surface. The sensing 
response for each PBG sensor pair is depicted in a different color and a different line format is 
used for each sensor within the pair (dashed line for wi = 120nm and solid line for wi = 
140nm). (a) Sensing response for the PBG sensing structures being functionalized with the MB 
probes. (b) Sensing response for the PBG sensing structures blocked with BSA. 
Besides the response (or lack of response for the BSA blocked structures) towards the 
target oligonucleotide, a remarkable instantaneous shift of the PBG edge position is observed 
for all the sensing structures within the chip when the solution with the target oligonucleotide 
reaches the sensors. This sharp shift lasts only around 2-3 minutes and the PBG edge is 
sharply back-shifted again to the initial position, as it can be clearly seen for the blocked 
sensing structures. That “up-and-down” shift indicates that an accumulation of the target 
oligonucleotide was produced in the tubing in the interface between the initial SSC 5X buffer 
and the oligonucleotide solution, producing a spectral shift caused by the increase of the 
refractive index of the medium. Nevertheless, after this transitory behavior, the nominal 
concentration of the target oligonucleotide is recovered and the refractive index of the 
medium goes back to the initial value. 
Regarding the sensitivity of the MB-functionalized PBG sensing structures towards the 
target oligonucleotide, net shifts of the PBG edge ranging from ~520 pm to even up to ~1100 
pm were obtained. These shifts represent a significant improvement in the sensitivity 
compared to those obtained using ring resonator based sensors, which are typically below 100 
pm [35,58], and are even higher to those obtained with those sensing structures using 
antibody-based amplification techniques [36]. Therefore, these shifts indicate a very high 
sensitivity of the selected PBG sensing structure towards small local refractive index 
variations being produced in its surface, as well as a very efficient recognition of the 
oligonucleotide targets by the MB probes used in the experiment. 
Finally, it is worth noting the tremendous influence of the structural parameters of the 
PBG sensing structures on their sensitivity. From Fig. 8(a) it can be seen that the PBG edge 
shift increases from ~520 pm to ~950 pm when the width of the transversal elements is 
simply increased from wi = 120nm to wi = 140nm for the first PBG sensor pair (depicted with 
blue color); for the second PBG sensor pair (depicted with red color), the PBG edge shift 
increases from ~800 pm to ~1100 pm for that 20 nm increase of the width of the transversal 
elements. Therefore, by properly selecting the structural parameters of the PBG sensing 
structure used in this work, a significant improvement in the sensitivity can be obtained 
without the need of increasing the footprint. This is a great advantage compared to other 
typical configurations of photonic sensing structures as ring resonators, where the sensitivity 
is limited by its working principle, or interferometers, where achieving higher sensitivities 
implies significantly increasing the size of the structure. On the other hand, this high 
influence of the structural parameters on the sensitivity also means a lower tolerance to 
fabrication deviations, as it can be observed from the different PBG edge shifts obtained for 
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sensing structures nominally having the same dimensions. Therefore, better fabrication 
reproducibility will be necessary for a repeatable and reliable operation of these sensors. 
5.3. Fluorescence test 
Once the oligonucleotide detection experiment was carried out, the PDMS flow cell was 
disassembled in order to measure the fluorescence of the labelled target oligonucleotide on 
the photonic chip. Fluorescence was observed selectively for the two PBG sensor pairs 
biofunctionalized with MB probes, as shown in Fig. 9(a). The quantification of that 
fluorescence is represented in Fig. 9(b), showing very high fluorescence intensity values on 
the positions where the MB probes were immobilized, thus confirming the recognition of the 
target oligonucleotides. On the other hand, the fluorescence intensity measured on the BSA 
blocked PBG sensing structures is extremely low, thus confirming the effectiveness of the 
blocking step. 
Fig. 9. (a) Fluorescence intensity observed on the photonic chip (left) after the oligonucleotide 
detection experiment and relative position on the chip (right). The shape of the microfluidic 
channel used in the experiment can be clearly observed. (b) Quantification of the fluorescence 
after the oligonucleotide detection experiment for the PBG sensor pairs. 
6. Conclusion
While our PBG structures do not have theoretical significantly higher bulk sensitivities 
(175nm/RIU) than other sensing structures (e.g., ring resonators, 80nm/RIU), we have been 
able to observe a PBG edge shift that is much greater in magnitude. This is due to the 
combination of an extremely high surface sensitivity of the PBG structures and a 
redistribution of matter produced by the conformational change suffered by the MB probes 
upon hybridization. 
Overall, the combination of the selected PBG sensing structures with the MB recognition 
probes has provided extremely high sensitivities towards the label-free detection of the target 
oligonucleotides, without the need of using any labelling method or increasing the much 
reduced footprint of the sensor. We expect that even higher sensitivities can be obtained by 
properly selecting the dimensions of the PBG structures, as observed from the obtained 
results, as well as by increasing the probe surface density [38,41]. This result opens the door 
for using this sensor configuration for the development of high sensitivity and highly 
multiplexed photonic based sensing chips for oligonucleotides detection with application in 
the biomedical field. 
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